Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tregs in ALS
NCT04055623Phase 2Completed
- Sponsor
- Houston Methodist Research Institute
- Start
- Aug 2019
- Primary completion
- Aug 2021
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) (3 arms), sponsored by Houston Methodist Research Institute. Primary endpoint: Change in Treg Suppressive Function in the Blood at 24 weeks. Started Aug 2019; status: completed.
02
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04055623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04055623.